Keratinocyte carcinomas (KC) are the most common malignant human neoplasms. Although surgery and destructive approaches are first-line treatments, topical therapies are commonly used. Due to limited uptake of topical agents across the skin barrier, clearance rates are often sub-optimal. In pre-clinical investigations, ablative fractional laser (AFL)-assisted drug delivery has demonstrated improved uptake of topical drugs commonly used to treat KC. In 22 clinical trials, the effect of AFL-assisted treatments has been investigated for actinic keratosis (AK; n = 14), Bowen's disease (BD; n = 5), squamous cell carcinoma (n = 1), and basal cell carcinoma (n = 7). The most substantial evidence currently exists for AFL-assisted photodynamic therapy for the treatment of AK and BD. AFL improved 12-months follow-up clearance rates of photodynamic therapy from 45.0–51.0% to 78.5–84.8% for AK and from 50.0–55.3% to 87.0–87.5% for BD. AFL-assisted pharmacological therapy is a promising tool for optimizing topical treatments of KC and its precursor lesions. Future developments include AFL-assisted immune activation, changing drug administration route of systemic therapies, and utilizing drug chemo-combinations.

角质形成细胞癌 (KC) 是最常见的人类恶性肿瘤。虽然手术和破坏性方法是一线治疗，但通常使用局部治疗。由于局部药物穿过皮肤屏障的吸收有限，清除率通常不是最佳的。在临床前研究中，消融点阵激光 (AFL) 辅助给药已证明改善了常用于治疗 KC 的局部药物的吸收。在 22 项临床试验中，研究了 AFL 辅助治疗对光化性角化病（AK；n  = 14）、鲍温病（BD；n  = 5）、鳞状细胞癌（n  = 1）和基底细胞癌（n = 7）。AFL 辅助光动力疗法治疗 AK 和 BD 目前存在最实质性的证据。AFL 将光动力疗法的 12 个月随访清除率从 AK 的 45.0-51.0% 提高到 78.5-84.8%，将 BD 的 50.0-55.3% 提高到 87.0-87.5%。AFL 辅助药物治疗是优化 KC 及其前体病变局部治疗的有前途的工具。未来的发展包括 AFL 辅助免疫激活、改变全身治疗的给药途径以及利用药物化学组合。